ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas

Introduction: Oxaliplatin (Oxa) is widely used in metastatic colorectal cancer (mCRC), but currently there are not valid predictors of response to this drug. In the control arms both of OPUS and PRIME studies Oxa seems more active in patients with mCRC with mutated (mt) KRAS than in those with wild...

Descripción completa

Detalles Bibliográficos
Autores principales: Orlandi, A., Di Salvatore, M., Bagalà, C., Basso, M., Strippoli, A., Plastino, F., Calegari, M.A., Cassano, A., Astone, A., Barone, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278917/
https://www.ncbi.nlm.nih.gov/pubmed/25553091
http://dx.doi.org/10.7150/jca.10478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278917/
https://www.ncbi.nlm.nih.gov/pubmed/25553091
http://dx.doi.org/10.7150/jca.10478

Ejemplares similares